A plant alkaloid.

Phase of research

Potential treatment - theoretical effect

How it helps


Drug status

Natural product

Supporting references
Contradictory references
Clinical trials

General information

Nicotine on PubChem

Marketed as


Dietary sources

Nicotiana genus plants
Structure not available


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor
Spike protein ACE2 Small molecule In silico
in silico 4.17

Predicted to bind (alone or in combination with favipiravir) the host ACE2 receptor in the presence of the SARS-CoV-2 spike (S) protein, which could block ACE2-S interaction.

Oct/17/2020 Oct/30/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04608201 Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients Recruiting Phase 3 Dec/09/2020 Dec/01/2021
NCT04598594 Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients Completed Phase 3 Nov/06/2020 Jun/20/2021
NCT04583410 Efficacy of Nicotine in Preventing COVID-19 Infection Recruiting Phase 3 Oct/22/2020 Jun/01/2022
NCT04583761 Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19) Completed Oct/14/2020 Feb/06/2021
NCT04429815 Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19 Completed Aug/25/2020 May/26/2021